Table 3.
Trials with Angiogenesis Inhibitors for Breast Cancer [16].
| TKI with Anti-Angiogenic Properties | |||||
| Study Name/NCT Identifier | Drug(s)/Novel Agent(s) | Study Phase | N | Primary Endpoint | Study Outcome |
|
SCRI BRE 122 NCT00887575 |
Neoadjuvant sunitinib + paclitaxel/carboplatin | I/II | 54 | pCR | Combo not recommended |
|
ZACFAST NCT00752986 |
Fulvestrant +/− vandetanib | II | 41 | EFS | Terminated |
|
NSABP FB-6 NCT00849472 |
Neoadjuvant AC ➔ +/− pazopanib | II | 101 | pCR | Increased toxicity; combo not recommended |
|
A4061010 NCT00076024 |
Docetaxel +/− Axitinib | I/II | 174 | TTP | Not significant |
|
RESILIENCE NCT01234337 |
Capecitabine +/− sorafenib | III | 519 | PFS | No advantage |
| Monoclonal Antibody | |||||
| Study Name/NCT Identifier | Drug(s)/Novel Agent(s) | Study Phase | N | Primary Endpoint | Study Outcome |
|
Rose/TRIO-12 NCT00703326 |
Docetaxel +/− ramucirumab | III | 1144 | PFS | No OS advantage |
Abbreviations: TKI = tyrosine kinase inhibitor, NCT = National Clinical Trials, EFS = event free survival; N = number of patients; OS = overall survival; pCR = complete pathologic response; PFS = progression free survival; TTP = time to progression.